CSE CALI  |  Last $0.13  |  Change -0.01 OTC FNNZF  |  Last $0.10  |  Change 0.00
  • Refined Resin Technologies is a cannabinoid research and refinery company that provides B2B and B2C products and services to licensed dispensaries and distributors in the medical cannabis supply chain.

  • Refined Resin has a facility in Oakland, California under a long-term lease, which it will retrofit a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in the first half of 2019.

  • Refined Resin also plans to provide white-labeling services to licensed brands and infused product manufacturers who do not have direct access to compliant production facilities.

  • Refined Resin’s principles have extensive experience in extraction, manufacturing and business operations.

  • Under the Royalty Agreement, FinCanna will earn a perpetual royalty ranging from 16% to 7% of Refined Resin’s consolidated annual revenues, based on agreed upon financial benchmarks and subject to certain buy-back options in exchange for funding US$3.5 million cash in tranches and US$1.295 million in shares of FinCanna.

  • The effective royalty rate to FinCanna is 11.75% on the first US$160 million of Refined Resin’s consolidated annual revenues.

To learn more about Refined Resin, visit: https://www.refinedresin.com/

For additional details on the Refined Resin royalty agreement, please see press releases dated February 15, 2018 and July 10, 2018

Subscribe for Updates